Cardiac

  • A catheter device is shown against a white background.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific posts positive data for coronary IVL catheter

    With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.

    By • May 19, 2026
  • An anatomical heart is pictured in red in a transparent body.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Artivion closes Endospan buyout to acquire recently approved heart device

    Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.

    By • May 19, 2026
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline➔
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • Boston Scientific's headquarters building is shown.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific buys $1.5B stake in TAVR developer MiRus

    The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

    By • May 18, 2026
  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J launches improved Shockwave catheter

    The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

    By • May 13, 2026
  • The Medtronic logo is displayed on an office building.
    Image attribution tooltip
    Retrieved from Medtronic on May 11, 2026
    Image attribution tooltip

    Medtronic to close California site amid restructuring

    The decision to wind down the operation in Santa Rosa in about two years comes as the medtech giant combines several businesses within its cardiovascular portfolio.

    By • May 11, 2026
  • Modern glass and metal office building with a reflective blue-tinted facade, set against a clear blue sky. In the foreground, a large black and white sign reads “Abbott” with the company’s stylized logo and the number “645.” The area has neatly cut grass and a few small trees.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Abbott gets FDA nod, CE mark for AI-enabled imaging device

    The device joins a portfolio of vascular technologies that generated 9.5% sales growth on a comparable basis in the first quarter.

    By • May 4, 2026
  • A closeup of the porcine heart valve against a white background.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic wins FDA approval for updated mitral replacement valve

    Surgeons have performed initial implants of the Mosaic Neo valve at centers across the U.S., as well as the first robotic implantation.

    By • April 29, 2026
  • A picture of a blue pulsed field ablation catheter against a gray background.
    Image attribution tooltip
    Courtesy of Johnson & Johnson MedTech
    Image attribution tooltip

    J&J starts head-to-head PFA trial against Boston Scientific device

    The study will compare outcomes on J&J’s Varipulse Pro platform and Boston Scientific’s rival Farapulse PFA system.

    By • April 28, 2026
  • Boston Scientific's Farawave pulsed field ablation catheter is shown against a white background.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    4 studies to know from HRS 2026

    Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where market share shifts in pulsed field ablation were on analysts’ minds.

    By • April 27, 2026
  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J to acquire Atraverse Medical

    The FDA-cleared radiofrequency guidewire will slot into J&J’s fast-growing cardiovascular portfolio.

    By • April 27, 2026
  • A corporate building for Edwards Lifesciences.
    Image attribution tooltip
    Courtesy of Edwards Lifesciences
    Image attribution tooltip

    Edwards raises 2026 forecast as TAVR sales surge

    The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott and Boston Scientific cut their full-year guidance.

    By • April 24, 2026
  • The exterior of Medtronic's Minnesota operational headquarters is shown along with its reflection in a pool of water.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic leads $100M investment in Pulnovo Medical

    Medtronic formed a commercial agreement with Pulnovo alongside its investment.

    By • April 21, 2026
  • The CathWorks FFRangio System on a cart.
    Image attribution tooltip
    Permission granted by CathWorks
    Image attribution tooltip

    Medtronic closes $585M purchase of CathWorks

    The deal is the second tuck-in acquisition this year for Medtronic, which has signaled its intent to pursue more M&A in its core business lines.

    By • April 20, 2026
  • A modern industrial building with beige and white walls and large blue-tinted glass windows. The name “Stryker” is mounted in black letters on the upper portion of the building. A white smokestack protrudes from the roof, and the sky is light and partly cloudy.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Stryker to buy Amplitude Vascular Systems

    Amplitude’s intravascular lithotripsy technology could emerge as a challenger to Shockwave IVL, Leerink Partners analyst Mike Kratky wrote.

    By • April 13, 2026
  • Pulse Biosciences' pulsed field ablation tool is displayed against a white background.
    Image attribution tooltip
    Permission granted by Pulse Biosciences
    Image attribution tooltip

    Pulse Biosciences hires Liane Teplitsky as COO

    The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.

    By • April 10, 2026
  • A picture of a blue pulsed field ablation catheter against a gray background.
    Image attribution tooltip
    Courtesy of Johnson & Johnson MedTech
    Image attribution tooltip

    J&J launches enhanced PFA device in Europe

    The Varipulse Pro pulsed field ablation platform, which has received a CE mark, will be a focus at the upcoming European Heart Rhythm Association annual meeting in Paris.

    By • April 7, 2026
  • Johnson & Johnson's Impella CP heart pump is shown in an illustration of the heart.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J’s Impella heart pump shows no patient benefit in 2 trials

    Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.

    By • April 1, 2026
  • The exterior of Medtronic's Minnesota operational headquarters is shown along with its reflection in a pool of water.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic wins CE mark for OmniaSecure defibrillation lead

    The device maker designed the lead to have the safety benefits of small-diameter devices without sacrificing durability.

    By • March 31, 2026
  • Medtronic's Symplicity Spyral device is shown against a white background.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic to study renal denervation combined with PCI

    Medtronic detailed plans to further study the blood pressure treatment while releasing additional data from the SPYRAL HTN trials that showed the procedure reduced hypertensive emergencies.

    By • March 31, 2026
  • A rendering of a rounded device with a wire structure surrounded by mesh.
    Image attribution tooltip
    Courtesy of Boston Scientific
    Image attribution tooltip

    Boston Scientific posts positive stroke prevention data for Watchman

    The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and efficacy goals in the closely watched CHAMPION-AF study.

    By • March 30, 2026
  • A physician in blue scrubs and a mask looks at Philips' DeviceGuide images on a large screen.
    Image attribution tooltip
    Courtesy of Philips
    Image attribution tooltip

    Philips wins FDA clearance for imaging device developed with Edwards

    The system uses AI to optimize the placement of Edwards’ mitral valve repair device.

    By • March 27, 2026
  • Silhouette of stressed businesswoman in the office.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Endologix to close production facility, lay off 31 people

    The company acquired the facility in the PQ Bypass takeover it struck in the aftermath of its bankruptcy filing.

    By • March 26, 2026
  • An illustration of the Medtronic OmniaSecure defibrillation lead in the heart.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic’s OmniaSecure defibrillation lead earns expanded FDA indication

    The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate the natural electrical system.

    By • March 25, 2026
  • Thermo Fisher Scientific
    Image attribution tooltip
    Courtesy of Thermo Fisher Scientific
    Image attribution tooltip

    Thermo Fisher completes $8.9B buyout of Clario

    Thermo Fisher plans to create a fast-growing business by integrating Clario’s data capture and management system with its existing capabilities.

    By • March 25, 2026
  • A closeup of JenaValve's Trilogy transcatheter valve to treat aortic regurgitation.
    Image attribution tooltip
    Permission granted by JenaValve
    Image attribution tooltip

    JenaValve snags FDA approval in aortic regurgitation

    The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.

    By • March 18, 2026